SBIR Phase II: Developing suspended microchannel resonators as a platform for personalized medicine in cancer

这项小企业创新研究（SBIR）二期项目的更广泛影响/商业潜力是确定多发性骨髓瘤（MM）患者的潜在治疗方法。新诊断的MM通常对各种治疗敏感，但在晚期复发是常见的。个性化分析将改善治疗决策。这个项目将为个性化医疗开发新的测试方法。虽然最初的目标是MM，但它可以潜在地应用于其他癌症或疾病。个性化医疗可以降低医疗成本、优化药物开发并改善患者护理。这个小企业创新研究（SBIR）二期项目将帮助开发方法和技术，用于提供指导多发性骨髓瘤（MM）患者治疗的新测试。该测试依赖于通过测量单个细胞的质量来解决暴露于各种药物选择后从患者身上收集的癌细胞的变化。今天MM是世界上第二大常见的血液恶性肿瘤。不幸的是，目前还没有生物标志物来确定MM患者的治疗易感性，以确定个性化的治疗方案。本项目旨在通过开发基于悬浮微通道谐振器（SMR）的高通量单细胞质量测量平台来解决这一问题，以解决药物对癌细胞的影响。在这个项目中，新一代具有单细胞成像、图像处理和细胞分类功能的SMR芯片将在3小时内分析20种药物。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to identify potential therapies for a multiple myeloma (MM) patients. Newly diagnosed MM is typically sensitive to a variety of therapies, but relapse is common in later stages. Personalized analysis would improve treatment decisions. This project will develop new testing for personalized medicine. Although the initial target is MM, this can potentially be applied to other cancers or diseases. Personalized medicine can lead to reduced healthcare costs, optimized drug development, and improved patient care.This Small Business Innovation Research (SBIR) Phase II project will help develop methods and techniques that will be used to offer new tests for guiding the treatment of multiple myeloma (MM) patients. The test relies on resolving changes of cancer cells collected from patients upon exposure to various drug options by measuring the mass of individual cells. Today MM is the second most common hematologic malignancy in the world. Unfortunately, today there are no biomarkers to define therapeutic susceptibility of MM patients to identify a personalized treatment regimen. This project aims to address this problem by developing a high-throughput single-cell mass measurement platform based on suspended microchannel resonators (SMR) to resolve the effects of the drugs on the cancer cells. In this project a new generation of SMR chips with linked single-cell imaging, image processing and cell classification will be developed to analyze a 20-drug panel in three hours.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.